94 Elma et al.
Investigación Clínica 65(1): 2024
methodology, validation, formal analysis,
investigation, resources, writing original
draft preparation, writing-review & editing;
RM: methodology, validation, formal analy-
sis, investigation, resources, writing-review
& editing; BY: methodology, software, for-
mal analysis, investigation, resources, data
curation, writing-review & editing, visual-
ization; EU: methodology, validation, inves-
tigation, resources, writing-review & edit-
ing; DA: methodology, validation, formal
analysis, writing original draft preparation,
writing-review & editing; TAC: conceptu-
alization, methodology, validation, formal
analysis, resources, writing original draft
preparation, writing-review & editing; BM:
conceptualization, methodology, validation,
formal analysis, resources, writing original
draft preparation, writing-review & edit-
ing; HS: conceptualization, methodology,
validation, formal analysis, investigation,
writing original draft preparation, writing-
review & editing, visualization, supervision,
project administration.
REFERENCES
1. García-Lledó A, Gómez-Pavón J, Gonzá-
lez del Castillo J, Hernández-Sampelayo
T, Martín-Delgado MC, Martín Sánchez
FJ, Martínez-Sellés M, Molero García JM,
Moreno Guillén S, Rodríguez-Artalejo F,
Ruiz-Galiana J, Cantón R, De Lucas Ra-
mos P, García-Botella A, Bouza E. Phar-
macological treatment of COVID-19: an
opinion paper. Rev Esp Quimioter 2021;
35(2): 115-130. https://doi.org/10.37201/
req/158.2021
2. Łagocka R, Dziedziejko V, Kłos P, Pawlik
A. Favipiravir in therapy of viral infections.
J Clin Med 2021; 10(2): 273. https://doi.
org/10.3390/jcm10020273
3. Pogue JM, McCreary EK. Coronavirus
disease 2019 treatment: a review of early
and emerging options. Open Forum In-
fect Dis 2020; 7(4): ofaa105. https://doi.
org/10.1093/ofid/ofaa105
4. Majewska A, Smyk JM. Favipiravir in the
battle with respiratory viruses. Mini Rev
Med Chem 2022; 22(17): 2224-2236.
https://doi.org/10.2174/1389557522666
220218122744
5. Favipiravir. National Institute of Child
Health and Human Development; 2006.
Bethesda (MD). Updated 15 February
2023. PMID: 32401463. https://www.ncbi.
nlm.nih.gov/pubmed/32401463
6. Lipsitch M, Sissoko D, Laouenan C, Fo-
lkesson E, M’Lebing A-B, Beavogui A-H,
Baize S, Camara A-M, Maes P, Shepherd
S, Danel C, Carazo S, Conde MN, Gala
J-L, Colin G, Savini H, Bore JA, Le Mar-
cis F, Koundouno FR, Petitjean F, Lamah
M-C, Diederich S, Tounkara A, Poelart
G, Berbain E, Dindart J-M, Duraffour S,
Lefevre A, Leno T, Peyrouset O, Irenge
L, Bangoura NF, Palich R, Hinzmann J,
Kraus A, Barry TS, Berette S, Bongo-
no A, Camara MS, Chanfreau Munoz V,
Doumbouya L, Souley H, Kighoma PM,
Koundouno FR, Réné L, Loua CM, Mas-
sala V, Moumouni K, Provost C, Samake
N, Sekou C, Soumah A, Arnould I, Ko-
mano MS, Gustin L, Berutto C, Camara
D, Camara FS, Colpaert J, Delamou L,
Jansson L, Kourouma E, Loua M, Mal-
me K, Manfrin E, Maomou A, Milinouno
A, Ombelet S, Sidiboun AY, Verreckt I,
Yombouno P, Bocquin A, Carbonnelle C,
Carmoi T, Frange P, Mely S, Nguyen V-K,
Pannetier D, Taburet A-M, Treluyer J-M,
Kolie J, Moh R, Gonzalez MC, Kuisma E,
Liedigk B, Ngabo D, Rudolf M, Thom R,
Kerber R, Gabriel M, Di Caro A, Wölfel
R, Badir J, Bentahir M, Deccache Y, Du-
mont C, Durant J-F, El Bakkouri K, Ga-
sasira Uwamahoro M, Smits B, Toufik N,
Van Cauwenberghe S, Ezzedine K, Dor-
tenzio E, Pizarro L, Etienne A, Guedj J,
Fizet A, Barte de Sainte Fare E, Murgue
B, Tran-Minh T, Rapp C, Piguet P, Pon-
cin M, Draguez B, Allaford Duverger T,
Barbe S, Baret G, Defourny I, Carroll M,
Raoul H, Augier A, Eholie SP, Yazdanpa-
nah Y, Levy-Marchal C, Antierrens A, Van
Herp M, Günther S, de Lamballerie X,
Keïta S, Mentre F, Anglaret X, Malvy D.
Experimental Treatment with Favipiravir
for Ebola Virus Disease (the JIKI Trial):